Key Findings
- 1How healthtech companies can build sustainable revenue from health data — ethically, legally, and at scale.
Overview
Health data is among the most valuable and most sensitive data categories. Monetising it requires navigating ethical, legal, and technical complexities that don't exist in other data businesses. Get it right, and you build a highly defensible, high-margin business. Get it wrong, and you face regulatory action, reputational damage, and patient harm.
"Get it right, and you build a highly defensible, high-margin business."
South Africa's doctor-to-patient ratio is 1:1,200 — telehealth could effectively triple specialist access.
Digital health infrastructure is no longer optional — it's the only path to equitable healthcare delivery.
Revenue Models
1. **Real-world evidence (RWE).** Pharmaceutical companies pay premium prices for anonymised patient outcome data that helps them understand how drugs perform in real-world settings versus clinical trials. A single RWE dataset can command R5-50 million depending on scope and quality.
Ratings and debt metrics reflect latest publicly available data (2025–2026), with some countries undergoing active restructuring. All data sourced from official publications, regulatory filings, and institutional research partners. Figures are indicative and may be subject to revision. Stock prices and index values are illustrative and do not represent real-time market data. IdeaToola does not provide financial advice. Verify critical data points with primary sources before making investment or strategic decisions.